# CS-206 in Patients With Sickle Cell Disease

> **NCT06565026** · EARLY_PHASE1 · RECRUITING · sponsor: **CorrectSequence Therapeutics Co., Ltd** · enrollment: 5 (estimated)

## Conditions studied

- Sickle Cell Disease

## Interventions

- **GENETIC:** CS-206

## Key facts

- **NCT ID:** NCT06565026
- **Lead sponsor:** CorrectSequence Therapeutics Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-02
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-06-30
- **Target enrollment:** 5 (ESTIMATED)
- **Last updated:** 2026-02-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06565026

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06565026, "CS-206 in Patients With Sickle Cell Disease". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06565026. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*